Reduced circulating BMP10 and BMP9 and elevated endoglin are associated with disease severity, decompensation and pulmonary vascular syndromes in patients with cirrhosis
Open Access
- 1 June 2020
- journal article
- research article
- Published by Elsevier BV in EBioMedicine
- Vol. 56, 102794
- https://doi.org/10.1016/j.ebiom.2020.102794
Abstract
No abstract availableKeywords
Funding Information
- British Heart Foundation
- Wellcome Trust
This publication has 48 references indexed in Scilit:
- Circulating Bmp10 acts through endothelial Alk1 to mediate flow-dependent arterial quiescenceDevelopment, 2013
- Soluble Endoglin Specifically Binds Bone Morphogenetic Proteins 9 and 10 via Its Orphan Domain, Inhibits Blood Vessel Formation, and Suppresses Tumor GrowthOnline Journal of Public Health Informatics, 2011
- Biological role of matrix metalloproteinases: a critical balanceEuropean Respiratory Journal, 2010
- Matrix Metalloproteinase-14 (MT1-MMP)–Mediated Endoglin Shedding Inhibits Tumor AngiogenesisCancer Research, 2010
- Bone Morphogenetic Protein (BMP) and Activin Type II Receptors Balance BMP9 Signals Mediated by Activin Receptor-like Kinase-1 in Human Pulmonary Artery Endothelial CellsOnline Journal of Public Health Informatics, 2009
- Bone Morphogenetic Protein-9 Is a Circulating Vascular Quiescence FactorCirculation Research, 2008
- Increased intrahepatic and circulating levels of endoglin, a TGF‐β1 co‐receptor, in patients with chronic hepatitis C virus infection: relationship to histological and serum markers of hepatic fibrosisJournal of Viral Hepatitis, 2006
- Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studiesJournal of Hepatology, 2006
- Systematic review: the model for end‐stage liver disease – should it replace Child‐Pugh's classification for assessing prognosis in cirrhosis?Alimentary Pharmacology & Therapeutics, 2005
- Hemodynamics and survival of patients with portopulmonary hypertensionLiver Transplantation, 2005